Uncategorized
Glaukos Completes Patient Enrollment in Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject®
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced the completion of patient enrollment in the initial phase of its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trial for the standalone version of the iStent inject® Trabecular Micro-Bypass Stent. T
